# Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

> **NCT06334757** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 46 (estimated)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Serplulimab
- **DRUG:** Bevacizumab Biosimilar HLX04
- **DRUG:** Pemetrexed
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06334757
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-08
- **Primary completion:** 2024-08-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2024-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06334757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06334757, "Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06334757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*